Novo Nordisk reports real‑world Wegovy pill results showing 6% weight loss in three months
Novo Nordisk presented real‑world data from patients who stayed on its daily oral Wegovy pill for three months. The average weight loss was 6.2% of body weight, equal to 6.3 kg (13.9 lb) from a baseline of 103.0 kg (227 lb). About 60% of participants lost at least 5% and roughly one‑sixth lost at least 10% of their weight. The findings were shared at the ObesityWeek conference and are intended to bolster Novo’s position against Eli Lilly in the U.S. oral obesity‑treatment market.
Why it matters
The data confirm that the oral formulation delivers weight‑loss results comparable to the drug’s late‑stage trial, supporting Novo’s claim of competitive efficacy. Investors may view the results as a catalyst for continued market share gains, especially as oral products now account for roughly one‑third of U.S. obesity prescriptions and Novo holds more than 80% of new oral orders.
Key facts
- 1Patients who remained on the daily oral Wegovy pill lost an average of 6.2% of body weight over three months. bdnews24.com
- 2The average loss equated to 6.3 kg (13.9 lb) from a baseline weight of 103.0 kg (227 lb). bdnews24.com
- 3Approximately three‑fifths of participants lost at least 5% of their weight. bdnews24.com
- 4Roughly one in six participants lost at least 10% of their weight. bdnews24.com
- 5The analysis included 5,872 adults who had never previously used a weight‑loss drug and stayed on the pill for the full three months. bdnews24.com
- 6Oral obesity treatments now represent about one‑third of U.S. prescriptions, with Novo securing over 80% of new oral prescriptions. bdnews24.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.